Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2016

01-05-2016 | Original Article

Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan

Authors: Wei-Chun Weng, Yu-Hui Huang, Shun-Fa Yang, Shian-Shiang Wang, Wu-Hsien Kuo, Chao-Wen Hsueh, Ching-Hsuan Huang, Ying-Erh Chou

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

The carcinogenesis of transitional cell carcinoma (TCC) of the urinary bladder involves etiological factors, such as ethnicity, the environment, genetics, and diet. Cluster of differentiation (CD44), a well-known tumor marker, plays a crucial role in regulating tumor cell differentiation and metastasis. This study investigated the effect of CD44 single nucleotide polymorphisms (SNPs) on TCC risk and clinicopathological characteristics. Five SNPs of CD44 were analyzed through real-time polymerase chain reaction in 275 patients with TCC and 275 participants without cancer. In this study, we observed that CD44 rs187115 polymorphism carriers with the genotype of at least one G were associated with TCC risk. Furthermore, TCC patients who carried at least one G allele at CD44 rs187115 had a higher stage risk than did patients carrying the wild-type allele (p < 0.05). In addition, The AATAC or GACGC haplotype among the five CD44 sites was also associated with a reduced risk of TCC. In conclusion, our results suggest that CD44 SNPs influence the risk of TCC. Patients with CD44 rs187115 variant genotypes (AG + GG) exhibited a higher risk of TCC; these patients may possess chemoresistance to developing late-stage TCC compared with those with the wild-type genotype. The CD44 rs187115 SNP may predict poor prognosis in patients with TCC.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Tung MC, Hsieh MJ, Wang SS, Yang SF, Chen SS, Wang SW, et al. Associations of VEGF-C genetic polymorphisms with urothelial cell carcinoma susceptibility differ between smokers and non-smokers in Taiwan. PLoS One. 2014;9:e91147.CrossRefPubMedPubMedCentral
3.
Bid HK, Manchanda PK, Mittal RD. Association of interleukin-1Ra gene polymorphism in patients with bladder cancer: case control study from north India. Urology. 2006;67:1099–104.CrossRefPubMed
4.
Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, Marsit CJ, et al. A case-control study of smoking and bladder cancer risk: emergent patterns over time. J Natl Cancer Inst. 2009;101:1553–61.CrossRefPubMedPubMedCentral
5.
Kellen E, Zeegers M, Paulussen A, Vlietinck R, Vlem EV, Veulemans H, et al. Does occupational exposure to pahs, diesel and aromatic amines interact with smoking and metabolic genetic polymorphisms to increase the risk on bladder cancer?; The belgian case control study on bladder cancer risk. Cancer Lett. 2007;245:51–60.
6.
7.
Pow-Sang JM, Seigne JD. Contemporary management of superficial bladder cancer. Cancer Control: J Moffitt Cancer Cent. 2000;7:335–9.
8.
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol: Off J Am Soc Clin Oncol. 2001;19:666–75.CrossRef
9.
10.
Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33–45.CrossRefPubMed
11.
Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11:254–67.CrossRefPubMed
12.
Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211–31.CrossRefPubMed
13.
Hill A, McFarlane S, Johnston PG, Waugh DJ. The emerging role of CD44 in regulating skeletal micrometastasis. Cancer Lett. 2006;237:1–9.CrossRefPubMed
14.
Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, Zoeller M. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med. 2008;8:784–804.CrossRefPubMed
15.
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104:973–8.CrossRefPubMedPubMedCentral
16.
Wang SJ, Bourguignon LY. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol. 2011;178:956–63.CrossRefPubMedPubMedCentral
17.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.CrossRefPubMedPubMedCentral
18.
Southgate J, Trejdosiewicz LK, Smith B, Selby PJ. Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines. Int J Cancer. 1995;62:449–56.CrossRefPubMed
19.
Ioachim E, Charchanti A, Stavropoulos N, Athanassiou E, Bafa M, Agnantis NJ. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. Anticancer Res. 2002;22:3383–8.PubMed
20.
Chien MH, Yang JS, Chu YH, Lin CH, Wei LH, Yang SF, et al. Impacts of CA9 gene polymorphisms and environmental factors on oral-cancer susceptibility and clinicopathologic characteristics in Taiwan. PLoS One. 2012;7:e51051.CrossRefPubMedPubMedCentral
21.
Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spielman RS, et al. Genetic analysis of genome-wide variation in human gene expression. Nature. 2004;430:743–7.CrossRefPubMedPubMedCentral
22.
Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007;67:9609–12.CrossRefPubMed
23.
Chou YE, Hsieh MJ, Chiou HL, Lee HL, Yang SF, Chen TY. CD44 gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features. BioMed Res Int. 2014;2014:231474.PubMedPubMedCentral
24.
Chou YE, Hsieh MJ, Hsin CH, Chiang WL, Lai YC, Lee YH, et al. CD44 gene polymorphisms and environmental factors on oral cancer susceptibility in taiwan. PLoS One. 2014;9:e93692.CrossRefPubMedPubMedCentral
25.
Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, et al. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17:6934–43.CrossRef
26.
Jiang L, Deng J, Zhu X, Zheng J, You Y, Li N, et al. CD44 rs13347 C > T polymorphism predicts breast cancer risk and prognosis in Chinese populations. Breast Cancer Research: BCR. 2012;14:R105.CrossRefPubMedPubMedCentral
27.
Vazquez A, Grochola LF, Bond EE, Levine AJ, Taubert H, Muller TH, et al. Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res. 2010;70:172–80.CrossRefPubMed
28.
Winder T, Ning Y, Yang D, Zhang W, Power DG, Bohanes P, et al. Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. Int J Cancer J Int Cancer. 2011;129:1096–104.CrossRef
29.
Zhou J, Nagarkatti PS, Zhong Y, Creek K, Zhang J, Nagarkatti M. Unique SNP in CD44 intron 1 and its role in breast cancer development. Anticancer Res. 2010;30:1263–72.PubMedPubMedCentral
30.
Sharma KL, Yadav A, Gupta A, Tulsayan S, Kumar V, Misra S, et al. Association of genetic variants of cancer stem cell gene CD44 haplotypes with gallbladder cancer susceptibility in North Indian population. Tumour Biol: J Int Soc Oncodev Biol Med. 2014;35:2583–9.CrossRef
31.
Su SC, Hsieh MJ, Chou YE, Fan WL, Yeh CB, Yang SF. Effects of rage gene polymorphisms on the risk and progression of hepatocellular carcinoma. Medicine. 2015;94:e1396.CrossRefPubMedPubMedCentral
32.
Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet. 2005;76:449–62.CrossRefPubMedPubMedCentral
33.
Hong RL, Pu YS, Chu JS, Lee WJ, Chen YC, Wu CW. Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Lett. 1995;89:81–7.CrossRefPubMed
34.
Muller M, Heicappell R, Habermann F, Kaufmann M, Steiner U, Miller K. Expression of CD44v2 in transitional cell carcinoma of the urinary bladder and in urine. Urol Res. 1997;25:187–92.CrossRefPubMed
35.
Uzgare AR, Xu Y, Isaacs JT. In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem. 2004;91:196–205.CrossRefPubMed
36.
Li Y, Liu W, Hayward SW, Cunha GR, Baskin LS. Plasticity of the urothelial phenotype: effects of gastro-intestinal mesenchyme/stroma and implications for urinary tract reconstruction. Differ Res Biol Divers. 2000;66:126–35.CrossRef
37.
Lipponen P, Aaltoma S, Kosma VM, Ala-Opas M, Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol. 1998;186:157–64.CrossRefPubMed
38.
Toma V, Hauri D, Schmid U, Ackermann D, Maurer R, Alund G, et al. Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol. 1999;155:1427–32.CrossRefPubMedPubMedCentral
39.
Hong RL, Pu YS, Hsieh TS, Chu JS, Lee WJ. Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol. 1995;153:2025–8.CrossRefPubMed
40.
Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011;121:1064–74.CrossRefPubMedPubMedCentral
41.
Kuniyasu H, Oue N, Tsutsumi M, Tahara E, Yasui W. Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3. Clin Cancer Res: Off J Am Assoc Cancer Res. 2001;7:4067–72.
42.
Miyoshi T, Kondo K, Hino N, Uyama T, Monden Y. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 1997;3:1289–97.
43.
Suenaga M, Yamada S, Fuchs BC, Fujii T, Kanda M, Tanaka C, et al. CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. J Surg Oncol. 2015;112:622–8.CrossRefPubMed
44.
Aaltomaa S, Lipponen P, Ala-Opas M, Kosma VM. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur Urol. 2001;39:138–44.CrossRefPubMed
45.
Di Cello F, Flowers VL, Li H, Vecchio-Pagan B, Gordon B, Harbom K, et al. Cigarette smoke induces epithelial to mesenchymal transition and increases the metastatic ability of breast cancer cells. Mol Cancer. 2013;12:90.CrossRefPubMedPubMedCentral
46.
Kokko LL, Hurme S, Maula SM, Alanen K, Grenman R, Kinnunen I, et al. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol. 2011;47:510–6.CrossRefPubMed
47.
Liu Y, Qing H, Su X, Wang C, Li Z, Liu S. Association of CD44 gene polymorphism with survival of NSCLC and risk of bone metastasis. Med Sci Monit: Int Med J Exp Clin Res. 2015;21:2694–700.CrossRef
48.
Esrig D, Spruck 3rd CH, Nichols PW, Chaiwun B, Steven K, Groshen S, et al. P53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 1993;143:1389–97.PubMedPubMedCentral
49.
50.
Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM, Schalken JA. P53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer. 1994;70:496–500.CrossRefPubMedPubMedCentral
51.
Kuncova J, Kostrouch Z, Viale M, Revoltella R, Mandys V. Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197. Folia Biol. 2005;51:3–11.
52.
Kuncova J, Urban M, Mandys V. Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells. APMIS. 2007;115:1194–205.CrossRefPubMed
53.
Hofmann M, Rudy W, Gunthert U, Zimmer SG, Zawadzki V, Zoller M, et al. A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res. 1993;53:1516–21.PubMed
54.
55.
Reisman DN, Strobeck MW, Betz BL, Sciariotta J, Funkhouser Jr W, Murchardt C, et al. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene. 2002;21:1196–207.CrossRefPubMed
56.
Strobeck MW, DeCristofaro MF, Banine F, Weissman BE, Sherman LS, Knudsen ES. The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression. J Biol Chem. 2001;276:9273–8.CrossRefPubMed
Metadata
Title
Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan
Authors
Wei-Chun Weng
Yu-Hui Huang
Shun-Fa Yang
Shian-Shiang Wang
Wu-Hsien Kuo
Chao-Wen Hsueh
Ching-Hsuan Huang
Ying-Erh Chou
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4566-9

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue

Original Article

Upregulated miRNA-622 inhibited cell proliferation, motility, and invasion via repressing Kirsten rat sarcoma in glioblastoma

Original Article

Combined analysis of pri-miR-34b/c rs4938723 and TP53 Arg72Pro with cervical cancer risk

Research Article

Wnt5a and Ror2 expression associate with the disease progress of primary thyroid lymphoma

Original Article

Downregulation of pyrroline-5-carboxylate reductase-2 induces the autophagy of melanoma cells via AMPK/mTOR pathway

Original Article

Nutrient deprivation-related OXPHOS/glycolysis interconversion via HIF-1α/C-MYC pathway in U251 cells

Original Article

MicroRNA-17 family as novel biomarkers for cancer diagnosis: a meta-analysis based on 19 articles
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits